Pertuzumab is an anti-cancer monoclonal antibody primarily indicated for the treatment of HER2-positive metastatic breast cancer. It is often used in conjunction with other agents like trastuzumab and docetaxel. Pertuzumab plays a significant role in inhibiting the HER2 receptor, which is overexpressed in certain breast cancers, thereby blocking signals that promote cancer cell growth. This targeted therapy is essential for patients who have not previously received chemotherapy for metastatic disease. Common side effects may include fatigue, nausea, and diarrhea, but these usually diminish over time. In simple terms, Pertuzumab helps target and inhibit the growth of specific breast cancer cells.
Pertuzumab binds to the HER2 receptor, preventing dimerization with other HER receptors, thereby inhibiting downstream signaling pathways that promote cell proliferation and survival in HER2-positive cancers.
No published brands for this salt yet.